• EVERY LIFE IS A LIFE WORTH FIGHTING FOR

  • AN UNDYING MISSION AGAINST RARE CANCER

  • LATEST NEWS


    Click me

HALF OF ALL PATIENTS ARE FIGHTING A RARE CANCER. – Memorial Sloan Kettering Cancer Center

RARE CANCER ISN’T RARE.

In the lifetime of an Average American:

270 Million people will be diagnosed with some form of cancer

127 Million of those people will die.

*AACR Annual Cancer Report, 2017

When taken in aggregate, “rare” cancers are the 3rd leading cause of death in the U.S. and account for nearly half of all cancer diagnoses. Defined as affecting fewer than 200,000 persons in the U.S., there are more than 250 known types of rare cancer.

3rd LEADING CAUSE OF DEATH IN U.S. TAKEN IN AGGREGATE

42% OF ALL CANCER DIAGNOSES ARE CONSIDERED RARE

250+ KNOWN TYPES OF RARE CANCER

Millions of people who could be saved should not be left to die.

RESEARCH & DEVELOPMENT

SHEPHERD is different from other pharmaceutical companies because we ask: “What approaches can save the lives of rare cancer patients?,” rather than: “What disease can I address with my approach?”

SHEPHERD is committed to developing a “new normal” – an ultra-fast, ultra-efficient process for rare cancers.

MEET THE SHEPHERD TEAM

EUGENE “GENE” WILLIAMS

Co-Founder & Advisory Board Chair
Gene Williams is the Executive Chairman of ProMIS Neurosciences, a publicly traded biotech focused on therapy development for Alzheimer’s disease. As former Senior Vice President of Program and Portfolio Management at Genzyme, Gene comes to SHEPHERD with expert knowledge on commercialization integration, drug development, and deal making.

Eugene

DAVID HYSONG

Founder, Patient & Chief Executive Officer

David is the founder and Chief Executive Officer of SHEPHERD and Executive Director of the SHEPHERD Foundation.  He is a Forbes 30 Under 30 honoree and Spotlight Health Scholar at the Aspen Institute. David was diagnosed with Adenoid Cystic Carcinoma, a rare form of head and neck cancer, in 2015. He combined the innovation, fearlessness, passion, determination and desire to save the lives of others, which had marked all of his previous endeavors, to found SHEPHERD with one goal in mind – to save the life of every rare cancer patient.

David

JOHANNE KAPLAN, PhD.

Chief Scientific Officer
Johanne comes to SHEPHERD from Genzyme, where she served as Vice President of Research. Over the course of her 24-year career in biotechnology, Johanne directed pioneering research and partnerships leading to the implementation of multiple clinical trials in the fields of gene therapy, autoimmunity, and oncology. She led the scientific research support of several approved drugs in the oncology space including alemtuzumab, clofarabine, and plerixafor.

Johanne

WILLIAM M. SIDERS, PhD.

Chief Development Officer

Dr. Siders joins SHEPHERD Therapeutics as Chief Development Officer to lead the validation and development of novel therapies for the treatment of rare cancers. Dr. Siders has spent the last 19 years of his career at Genzyme/Sanofi and was a pioneer in early efforts in the field of cancer immunotherapy. Most recently, Dr. Siders was responsible for leading the Neuroimmunology Research Group focusing on the identification and validation of therapeutic targets for multiple sclerosis. He has been involved with several research and development programs including alemtuzumab and teriflunomide.

Bill

ELIZABETH (HOSTETTER) DENISON

Chief Operating Officer
Elizabeth joins SHEPHERD having spent most of her career as a consultant at Bain & Company, where she advised companies across sectors to grow profitability, optimize costs and launch commercial products. At Bain, Elizabeth developed a passion for analytical problem solving, processes, team building—and most importantly— a renewed commitment to healthcare.

Elizabeth

JAMIE DEMPSEY BARBER, PhD.

Chief Research Officer
Jamie is former head teaching fellow for both molecular and cellular biology courses at Harvard University, as well as instructor of “The Biology of Cancer” course at Harvard Extension School. Her expertise covers cancer-related molecular and cellular mechanisms, as well as therapeutic management.

Jamie

DANIEL ELKINS

Director of Government Affairs

Mr. Elkins currently serves as the Director of Government Affairs for SHEPHERD. Mr. Elkins has successfully worked with multiple startups to fundraise, develop prototypes, bring concepts to market, and assist in strategic operational planning

Daniel

MAHTA SAMIZADEH, PhD.

Senior Scientist
Dr. Mahta Samizadeh is a pharmaceutical scientist and pharmacist, with nearly ten years of experience in designing polymeric drug delivery systems and performing physicochemical, biological and efficacy characterization, and expertise in mucosal immunity and inflammation.

Mahta

KATHERINE ARLINE

Information Officer
Kate joins SHEPHERD with a diverse background that spans design, development, analysis, and entrepreneurship. As the principle at her development venture she both worked with and advised over a hundred companies, from startups to the Fortune 500. Before joining SHEPHERD, she was the CEO of a Harvard-backed startup focused on using analytics and technology to improve the welfare of healthcare’s underserved. She brings a data-driven approach to the search for new development opportunities — and the motivation of a rare cancer caregiver.

Katherine

NANNAN JIA

Research Associate

Nannan has over 3 years’ experience with molecular and cell biology. From Shanghai to Boston, from academy to industry, her major experience covers cell line/primary cell culture, hESCs/mSCs culture, Western Blot, ELISA, PCR, qPCR, genome editing by CRISPR/CAS9, high thoughput compound screening. Nannan holds a B.A. in Biology and Medical Studies.  Nannan enjoys baking, cooking, reading and photography.

Nannan

LACIE RANDALL

Chief Creative Officer
With an intensive background in Marketing and Communication, Lacie has helped create multiple American Advertising Award-winning campaigns for both nonprofit and for-profit organizations. Her recent work includes such companies as Major League Baseball and the National Football League, Publix, and Hermès.

Lacie

ELLE ROSS

Governmental Relations Counsel

Elle Ross serves as Government Relations Counsel at SHEPHERD.  She also concurrently serves as legislative counsel and Manager of Army Programs at the National Guard Association advocating for operational reserve forces.

Elle

RODRIGO BRAVO

Senior Research Analyst

Rod Bravo is a Gates Millennium Scholar who graduated from Harvard College in 2016 with a concentration in cognitive neuroscience and evolutionary psychology, with significant additional coursework in neurobiology and health policy.

Rod

LOUIE TREUTING

Mathematical Analyst

SHEPHERD welcomes Louie, a scholar of applied mathematics and computation. His work entails researching and developing modern methods behind drug combination and synergy, as well as engineering novel machine learning methods for SHEPHERD’s proprietary discovery engine.

Louie

The SHEPHERD Foundation

HISTORY

A Rage to Live

David Hysong has had a lifelong desire to risk his own life to save the lives of others. When an early cancer diagnosis blocked his intended path in Special Operations and anti-human trafficking work, he forged another. One that has the potential to save far more lives than he had ever dreamed. At SHEPHERD, we want to be a “million life idea.” And that is the SHEPHERD promise – to never stop fighting until every rare cancer patient lives.

STAY IN TOUCH

We’d love to keep you involved every step of the way. Just complete the form below and you’re in…

CAMBRIDGE: 114 Western Avenue, Allston, MA 02134

NATICK: ABI-LAB, 27 Strathmore Road, Natick, MA 01760

NASHVILLE: 1212 Laurel Street, #1403, Nashville, TN 37203